NCT07619495Completed
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk
Comparative Effectiveness of Semaglutide and Dulaglutide in Patients at Low, Moderate, and High Cardiovascular Risk With Type 2 Diabetes and Overweight
Source: ClinicalTrials.gov · Last updated 9 Jul 2026
Brief summary (registry, in English)
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 120000 (actual)
- First submitted
- 23 May 2026
- Start date
- 20 Jan 2026
- Primary completion date
- 1 Jun 2026
- Lead sponsor
- Brigham and Women's Hospital
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT07619495
What you commit to
- Study type: Observational
- Participants enrolled: 120000
- From 20 Jan 2026 to the primary completion date, 1 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior use of pramlintide or any GLP-1-RA, except semaglutide or dulaglutide
Other illness
- MEN syndrome type 2
- Malignancy
- Type 1 diabetes
- Secondary diabetes
- End-stage renal disease or dialysis
- History of bariatric surgery
Other
- Medullary thyroid carcinoma
- Uncontrolled diabetic retinopathy or maculopathy
- Pregnancy
- Cardiovascular event or intervention in the last 7 days
Who the study is looking for
- Men or women aged 18 years or older
- History of myocardial infarction, stroke, any surgical or percutaneous revascularization procedure
- Use of antihypertensive or lipid-lowering drugs
- Coronary, carotid, or peripheral artery disease
- BMI greater than or equal to 25.0 mg/m2
- Type 2 diabetes
Criteria the registry did not label
- Study Period:
- Optum: Eligible cohort entry period between December 5, 2017 to November 30, 2025.
- MarketScan: Eligible cohort entry period between December 5, 2017 to September 30, 2023.
- Medicare: Eligible cohort entry period between December 5, 2017 to September 30, 2020.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Brigham and Women's Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.